1. US Institute of Medicine . Committee on the Assessment of the US Drug Safety System. The future of drug safety—promoting and protecting the health of the public. In: Baciu A Stratton K Burke SP , eds. Committee on the Assessment of the US Drug Safety System, Board on Population Health and Public Health Practice. The National Academies Press, 2006.
2. Rosiglitazone, marketing, and medical science
3. The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment
4. The Erice Declaration
5. European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. 2010. https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-suspension-avandia-avandamet-avaglim.